Immatics N.V. Stock Forecast
NASDAQ: IMTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 7.37 0.00%
IMTX analyst consensus
Consensus (8 analysts)
none
Avg. price target
$17.63+139.21%
- Strong buy 0
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Immatics N.V. (2026-10-08), 8 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $17.63, with a high estimate of $25.00 and a low estimate of $11.80. The average target implies upside of 139.2% from the current price of $7.37.
The spread between the highest and lowest targets is 111.9%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IMTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 8 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $11.80 | +60.11% |
| Average target | $17.63 | +139.21% |
| High target | $25.00 | +239.21% |